Skip to content

Discrimination of DILI and AIH by Artificial Intelligence

Development and Validation of a Machine Learning Model to Differentiate Drug-induced Liver Injury and Autoimmune Hepatitis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05532345
Enrollment
2583
Registered
2022-09-08
Start date
2022-07-01
Completion date
2023-05-31
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Hepatitis, Drug-induced Liver Injury

Keywords

Artificial intelligence, Differential diagnose

Brief summary

A retrospective, multi-center, non-interventional cohort study has been going to explore whether artificial intelligence can discriminate Drug-induced liver injury and Autoimmune hepatitis. A machine learning-based tool will be developed and validated to help clinicians to differentiate between Drug-induced liver injury and Autoimmune hepatitis

Detailed description

Research Objectives: 1. To develop a machine learning-based model from retrospective data. 2. To validate the machine learning-based model from internal dataset and external datasets nationwide. 3. To setup a website or application based on the above model to discriminate Drug-induced liver injury and Autoimmune hepatitis.

Interventions

None listed

Sponsors

Beijing Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Drug-induced liver injury 1. RUCAM ≥6 and met one of the following biochemical conditions: a.) ALT≥5 ULN, b.) or ALP ≥2 ULN, iii) or ALT≥3 ULN and TBil≥2 ULN. 2. RUCAM was between 3-5, the medical records were further reviewed by the three authors to determine the eligibility. * Autoimmune hepatitis 1. The revised International Autoimmune Hepatitis Group (IAIHG) diagnostic score≥6 points. 2. Liver biopsy available, which is compatible with typical features of AIH. 3. If liver biopsy was unavailable, patients who achieved biochemical resolution after sustained immunosuppressive therapy.

Exclusion criteria

* Drug-induced liver injury 1. Hepatotropic viral infection: hepatitis A, B, C, D and E. 2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc. 3. Hypoxic ischemic hepatitis and congestive liver disease. 4. Alcohol consumption: male \>40g/d, female \>20g/d, and ≥5 years. 5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. Autoimmune hepatitis. 7. Parasitic infection. 8. Sepsis. 9. Previous liver transplantation or bone marrow transplantation. 10. Pregnancy or lactation. 11. Genetic and metabolic liver diseases. * Autoimmune hepatitis 1. Hepatotropic viral infection: hepatitis A, B, C, D and E. 2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc. 3. Hypoxic ischemic hepatitis and congestive liver disease. 4. Alcohol consumption: male \>40g/d, female \>20g/d, and ≥5 years. 5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. Drug-induced liver injury. 7. Parasitic infection. 8. Sepsis. 9. Previous liver transplantation or bone marrow transplantation. 10. Pregnancy or lactation. 11. Genetic and metabolic liver diseases.

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of the model in the differential diagnosis of DILI and AIHMay 31, 2023The ratio of the correct number of forecasts to the total number of forecasts
The confidence of the model in the differential diagnosis of DILI and AIHMay 31, 2023The confidence and 95% confidence internal of the model in determining whether each case is DILI or AIH

Countries

China

Contacts

STUDY_CHAIRXinyan Zhao, Dr.

Beijing Friendship Hospital

PRINCIPAL_INVESTIGATORYing Sun, Dr.

The Fifth Medical Department of the PLA

PRINCIPAL_INVESTIGATORJing Zhang, Dr.

Capital Medical University Affiliated Beijing You'an Hospital

PRINCIPAL_INVESTIGATORJia Li, Dr.

Tianjin Second People's Hospital

PRINCIPAL_INVESTIGATORLiang Wang, Dr.

Lanzhou University Affiliated Second Hospital

PRINCIPAL_INVESTIGATORXiaoli Hu, Dr.

Heilongjiang Provicial Hospital

PRINCIPAL_INVESTIGATORJingshou Chen, Dr.

The First Affiliated Hospital of Xiamen University

PRINCIPAL_INVESTIGATORFeng Guo, Dr.

Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine

PRINCIPAL_INVESTIGATORPingying Li, Dr.

Qinghai People's Hospital

PRINCIPAL_INVESTIGATORQiuju Tian, Dr.

The Affiliated Hospital of Qingdao University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026